Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

Clinical Trial
.2015 Jul 4;386(9988):31-45.
doi: 10.1016/S0140-6736(15)60721-8. Epub 2015 Apr 23.

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

Clinical Trial

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

RTS,S Clinical Trials Partnership. Lancet..

Erratum in

  • Department of Error.
    [No authors listed][No authors listed]Lancet. 2015 Jul 4;386(9988):30. doi: 10.1016/S0140-6736(15)60643-2. Epub 2015 May 6.Lancet. 2015.PMID:26169866No abstract available.

Abstract

Background: The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, we report the final results from the same trial, including the efficacy of a booster dose.

Methods: From March 27, 2009, until Jan 31, 2011, children (age 5-17 months) and young infants (age 6-12 weeks) were enrolled at 11 centres in seven countries in sub-Saharan Africa. Participants were randomly assigned (1:1:1) at first vaccination by block randomisation with minimisation by centre to receive three doses of RTS,S/AS01 at months 0, 1, and 2 and a booster dose at month 20 (R3R group); three doses of RTS,S/AS01 and a dose of comparator vaccine at month 20 (R3C group); or a comparator vaccine at months 0, 1, 2, and 20 (C3C [control group]). Participants were followed up until Jan 31, 2014. Cases of clinical and severe malaria were captured through passive case detection. Serious adverse events (SAEs) were recorded. Analyses were by modified intention to treat and per protocol. The coprimary endpoints were the occurrence of malaria over 12 months after dose 3 in each age category. In this final analysis, we present data for the efficacy of the booster on the occurrence of malaria. Vaccine efficacy (VE) against clinical malaria was analysed by negative binomial regression and against severe malaria by relative risk reduction. This trial is registered with ClinicalTrials.gov, numberNCT00866619.

Findings: 8922 children and 6537 young infants were included in the modified intention-to-treat analyses. Children were followed up for a median of 48 months (IQR 39-50) and young infants for 38 months (34-41) after dose 1. From month 0 until study end, compared with 9585 episodes of clinical malaria that met the primary case definition in children in the C3C group, 6616 episodes occurred in the R3R group (VE 36·3%, 95% CI 31·8-40·5) and 7396 occurred in the R3C group (28·3%, 23·3-32·9); compared with 171 children who experienced at least one episode of severe malaria in the C3C group, 116 children experienced at least one episode of severe malaria in the R3R group (32·2%, 13·7 to 46·9) and 169 in the R3C group (1·1%, -23·0 to 20·5). In young infants, compared with 6170 episodes of clinical malaria that met the primary case definition in the C3C group, 4993 episodes occurred in the R3R group (VE 25·9%, 95% CI 19·9-31·5) and 5444 occurred in the R3C group (18·3%, 11·7-24·4); and compared with 116 infants who experienced at least one episode of severe malaria in the C3C group, 96 infants experienced at least one episode of severe malaria in the R3R group (17·3%, 95% CI -9·4 to 37·5) and 104 in the R3C group (10·3%, -17·9 to 31·8). In children, 1774 cases of clinical malaria were averted per 1000 children (95% CI 1387-2186) in the R3R group and 1363 per 1000 children (995-1797) in the R3C group. The numbers of cases averted per 1000 young infants were 983 (95% CI 592-1337) in the R3R group and 558 (158-926) in the R3C group. The frequency of SAEs overall was balanced between groups. However, meningitis was reported as a SAE in 22 children: 11 in the R3R group, ten in the R3C group, and one in the C3C group. The incidence of generalised convulsive seizures within 7 days of RTS,S/AS01 booster was 2·2 per 1000 doses in young infants and 2·5 per 1000 doses in children.

Interpretation: RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the vaccine has the potential to make a substantial contribution to malaria control when used in combination with other effective control measures, especially in areas of high transmission.

Funding: GlaxoSmithKline Biologicals SA and the PATH Malaria Vaccine Initiative.

Copyright © 2015 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests

PAl’s institute has received grants from the Catalan Government, the Spanish Government, Medicines for Malaria Venture, and the Bill & Melinda Gates Foundation. PAl has received personal fees from Medicines for Malaria Venture. DCM, CMai, PN, and LO’s institutes have received grants from MVI for other malaria studies. AMo has received personal fees from Medicines for Malaria Venture and GlaxoSmithKline. CO and KO’s institutes have received grants from the Malaria Clinical Trial Alliance. LO has received financial support from GlaxoSmithKline to participate to scientific congresses and to set up the “Trust in Science” grant. MT is a board member of the Optimus Foundation, and his institution is reimbursed for his activities on the Scientific Advisory Board of the Novartis Institute for Tropical Diseases. MT has also received for his institution other grants from MVI and from the Bill & Melinda Gates Foundation, and travel reimbursements from MVI and Sanaria. WRB, JCoh, YG, DH, EJ, DLa, AL, MLi, OO-A, AOli, and JV are, or were at the time of the study, employed by the GlaxoSmithKline group of companies. JCoh is an independent consultant for GSK Vaccines. JCoh, EJ, DLa, and OO-A have shares or stock options in the GlaxoSmithKline group of companies. JCoh and WRB are named inventors on patents for which the rights have been assigned to GlaxoSmithKline group of companies. DK, DLe, CO, and BS are or were at the time of the study employees at PATH MVI. DSc is employed by the London School of Hygiene & Tropical Medicine, and his consultancy activities for the MVI are funded as a grant to the London School of Hygiene & Tropical Medicine by MVI. All other members of the RTS,S Clinical Trials Partnership declare no competing interests.

Figures

Figure 1
Figure 1. Trial profile for participants aged 5–17 months
Participants’ flow in the study in those enrolled in the 5–17months age category. ITT=intention to treat. *For 70 children, the screeningdata had not been reported before the database freeze of the previous analysesand these participants were not included in the CONSORT charts publishedpreviously. †During monitoring, one participant was found to have beenenrolled twice at two different clinics under two different participant numbers.This participant was excluded from the per-protocol analyses. Because of theremoval of one participant number from the database, the total number ofparticipants enrolled into the study changed from 15 460 (8923 in the5–17 months age group), as reported in previous analyses, to 15 459participants (8922 in the 5–17 months age group) in the final analysesreported here. ‡2867 children in the with booster group, 2887 in thewithout booster group, and 2905 in the control group received doses 1 and 2.
Figure 2
Figure 2. Trial profile for participants aged 6–12 weeks
Participants’ flow in the study in those enrolled in the 6–12 weeksage category. ITT=intention to treat. *For 118 infants, the screening data hadnot been reported before the database freeze of the previous analyses and theseparticipants were not included in the CONSORT charts published previously.†2115 children in the with booster group, 2119 in the without boostergroup, and 2134 in the control group received doses 1 and 2. ‡For someparticipants, consent to the extension occurred before visit 34. One participantconsented to the extension but died before visit 34. This participant isconsidered as enrolled into the extension and the reason for not undertakingvisit 38 is recorded as died.
Figure 3
Figure 3. Vaccine efficacy against clinical and severe malaria by study site in the 5–17 months age category
VE against all episodes of clinical malaria (primary case definition) in (A) theR3C group and (B) the R3R group from month 0 to study end; and VE against severemalaria (primary case definition) in (C) the R3C group and (D) the R3R groupfrom month 0 to study end. Study sites are ordered from lowest (Kilifi) tohighest (Siaya) incidence of clinical malaria (secondary case definition)measured in control infants 6–12 weeks of age at enrolment during 12months of follow-up. pinteraction not calculated for (C) or (D).Analyses were by modified intention to treat. Bars are 95% CIs. The size of eachsquare is proportional to the number of participants enrolled at each studysite. The following numbers of children aged 5–17 months were enrolled bysite for all three groups (R3R, R3C, and C3C) together: 600 in Kilifi, 912 inKorogwe, 1002 in Manhiça, 704 in Lambaréné, 903 inBagamoyo, 800 in Lilongwe, 600 in Agogo, 1000 in Kombewa, 1002 in Kintampo, 600in Nanoro, and 799 in Siaya. R3C=RTS,S/AS01 primary schedule without booster.C3C=control group. R3R=RTS,S/AS01 primary schedule with booster. VE=vaccineefficacy.
Figure 4
Figure 4. Cases of clinical and severe malaria averted at each site during 48 months of follow-up in the 5–17 months age category
Analyses were by modified intention to treat. Data are ordered by increasingmalaria incidence at each study site. Cases averted of (A) clinical malaria(secondary case definition) and (B) severe malaria (secondary case definition)between month 0 and study end. The secondary case definition of severe malariawas used for this analysis because, during routine clinical practice, thesechildren would normally receive a full course of antimalarial treatment.R3C=RTS,S/AS01 primary schedule without booster. R3R=RTS,S/AS01 primary schedulewith booster.
Figure 5
Figure 5. Vaccine efficacy against clinical and severe malaria by study site in the 6–12 weeks age category
VE against all episodes of clinical malaria (primary case definition) in (A) theR3C group and (B) the R3R group from month 0 to study end; and VE against severemalaria (primary case definition) in (C) the R3C group and (D) the R3R groupfrom month 0 to study end. Study sites are ordered from lowest (Kilifi) tohighest (Siaya) modified incidence of clinical malaria (secondary casedefinition) measured in control infants 6–12 weeks of age at enrolmentduring 12 months of follow-up. Analyses were by modified intention to treat.Bars are 95% CIs. The size of each square is proportional to the number ofparticipants enrolled at each study site. The following numbers of infants aged6–12 weeks were enrolled by site for all three groups (R3R, R3C, and C3C)together: 304 in Kilifi, 593 in Korogwe, 635 in Manhiça, 226 inLambaréné, 802 in Bagamoyo, 826 in Lilongwe, 688 in Agogo, 631 inKombewa, 331 in Kintampo, 681 in Nanoro, and 820 in Siaya. C3C=control group.R3C=RTS,S/AS01 primary schedule without booster. R3R=RTS,S/AS01 primary schedulewith booster. VE=vaccine efficacy.
Figure 6
Figure 6. Cases of clinical and severe malaria averted at each site during 38 months of follow-up in the 6–12 weeks age category
Analyses were by modified intention to treat. Data are ordered by increasingmalaria incidence at each study site. Cases averted of (A) clinical malaria(secondary case definition) and (B) severe malaria (secondary case definition)between month 0 and study end. The secondary case definition of severe malariawas used for this analysis because, during routine clinical practice, thesechildren would normally receive a full course of antimalarial treatment.R3C=RTS,S/AS01 primary schedule without booster. R3R=RTS,S/AS01 primary schedulewith booster.
See this image and copyright information in PMC

Comment in

Similar articles

  • Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa.
    Otieno L, Guerra Mendoza Y, Adjei S, Agbenyega T, Agnandji ST, Aide P, Akoo P, Ansong D, Asante KP, Berkley JA, Gesase S, Hamel MJ, Hoffman I, Kaali S, Kamthunzi P, Kariuki S, Kremsner P, Lanaspa M, Lell B, Lievens M, Lusingu J, Malabeja A, Masoud NS, Mtoro AT, Njuguna P, Ofori-Anyinam O, Otieno GA, Otieno W, Owusu-Agyei S, Schuerman L, Sorgho H, Tanner M, Tinto H, Valea I, Vandoolaeghe P, Sacarlal J, Oneko M.Otieno L, et al.Vaccine. 2020 Jan 22;38(4):897-906. doi: 10.1016/j.vaccine.2019.10.077. Epub 2019 Nov 7.Vaccine. 2020.PMID:31708182Free PMC article.Clinical Trial.
  • Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y, Garric E, Leach A, Lievens M, Ofori-Anyinam O, Pirçon JY, Stegmann JU, Vandoolaeghe P, Otieno L, Otieno W, Owusu-Agyei S, Sacarlal J, Masoud NS, Sorgho H, Tanner M, Tinto H, Valea I, Mtoro AT, Njuguna P, Oneko M, Otieno GA, Otieno K, Gesase S, Hamel MJ, Hoffman I, Kaali S, Kamthunzi P, Kremsner P, Lanaspa M, Lell B, Lusingu J, Malabeja A, Aide P, Akoo P, Ansong D, Asante KP, Berkley JA, Adjei S, Agbenyega T, Agnandji ST, Schuerman L.Guerra Mendoza Y, et al.Hum Vaccin Immunother. 2019;15(10):2386-2398. doi: 10.1080/21645515.2019.1586040. Epub 2019 Apr 23.Hum Vaccin Immunother. 2019.PMID:31012786Free PMC article.Clinical Trial.
  • First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.
    RTS,S Clinical Trials Partnership; Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BG, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R, Mtoro A, Sykes A, Ahmed S, Urassa AM, Ali AM, Mwangoka G, Tanner M, Tinto H, D'Alessandro U, Sorgho H, Valea I, Tahita MC, Kaboré W, Ouédraogo S, Sandrine Y, Guiguemdé RT, Ouédraogo JB, Hamel MJ, Kariuki S, Odero C, Oneko M, Otieno K, Awino N, Omoto J, Williamson J, Muturi-Kioi V, Laserson KF, Slutsker L, Otieno W, Otieno L, Nekoye O, Gondi S, Otieno A, Ogutu B, Wasuna R, Owira V, Jones D, Onyango AA, Njuguna P, Chilengi R, Akoo P, Kerubo C, Gitaka J, Maingi C, Lang T, Olotu A, Tsofa B, Bejon P, Peshu N, Marsh K, Owusu-Agyei S, Asante KP, Osei-Kwakye K, Boahen O, Ayamba S, Kayan K, Owusu-Ofori R, Dosoo D, Asante I, Adjei G, Adjei G, Chandramohan D, Greenwood B, Lusingu J, Gesase S, Malabeja A, Abdul O, Kilavo H, Mahende C, Liheluka E, Lemnge M, Theander T, Drakeley C, Ansong D, Agbenyega T, Adjei S, Boateng HO, Ret…See abstract for full author list ➔RTS,S Clinical Trials Partnership, et al.N Engl J Med. 2011 Nov 17;365(20):1863-75. doi: 10.1056/NEJMoa1102287. Epub 2011 Oct 18.N Engl J Med. 2011.PMID:22007715Clinical Trial.
  • Clinical development of RTS,S/AS malaria vaccine: a systematic review of clinical Phase I-III trials.
    Agnandji ST, Fernandes JF, Bache EB, Ramharter M.Agnandji ST, et al.Future Microbiol. 2015;10(10):1553-78. doi: 10.2217/fmb.15.90. Epub 2015 Oct 6.Future Microbiol. 2015.PMID:26437872Review.
  • From the circumsporozoite protein to the RTS, S/AS candidate vaccine.
    Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A.Cohen J, et al.Hum Vaccin. 2010 Jan;6(1):90-6. doi: 10.4161/hv.6.1.9677. Epub 2010 Jan 30.Hum Vaccin. 2010.PMID:19806009Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. WHO. World Malaria Report, 2014. Geneva: World Health Organization; 2014.
    1. Gordon DM, McGovern TW, Krzych U, et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J Infect Dis. 1995;171:1576–85. - PubMed
    1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum Vacc. 2010;6:90–96. - PubMed
    1. Kester KE, Cummings JF, Ofori-Anyinam O, et al. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009;200:337–46. - PubMed
    1. Lell B, Agnandji S, von Glasenapp I, et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One. 2009;4:e7611. - PMC - PubMed

Publication types

MeSH terms

Substances

Associated data

Related information

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp